B6-hVEGFA Mouse
Product Name
B6-hVEGFA Mouse
Product ID
C001555
Strain Name
C57BL/6JCya-Vegfatm1(hVEGFA)/Cya
Backgroud
C57BL/6JCya
Note
One of Cyagen’s HUGO-GTTM (Humanized Genomic Ortholog for Gene Therapy) Strains
When using this mouse strain in a publication, please cite “B6-hVEGFA Mouse (Catalog C001555) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
VPF, VEGF, MVCD1
NCBI ID
Chromosome
Chr 6
MGI ID
Datasheet
Strain Description
The Vascular Endothelial Growth Factor (VEGF) family is a group of particular endothelial growth factors intimately associated with angiogenesis. These factors promote increased vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration and proliferation, and are capable of stimulating angiogenesis and increasing the permeability of existing vessels. As such, they play a pivotal role in normal vascular development and wound healing. The VEGF family comprises VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PLGF [1]. Of these, VEGFA is the most commonly targeted in research related to neovascular ophthalmic diseases due to its crucial role in the proliferation, migration, and formation of endothelial cell microvessels [2]. Overexpression of VEGFA in the eye can result in abnormal vascular growth and leakage, leading to various ophthalmic diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and corneal neovascularization [2-3]. The progression of solid tumors depends on vascularization and angiogenesis within malignant tissues, with VEGFA playing a crucial role among various pro-angiogenic factors. The VEGFA gene is upregulated in many known tumors, correlating with tumor staging and progression. Blocking VEGFA may lead to vascular network regression, thereby inhibiting tumor growth[4]. Thus, VEGFA is an important target for anti-angiogenic cancer therapies.
The B6-hVEGFA mice were generated by replacing the mouse Vegfa gene sequence with the human VEGFA gene sequence, including the non-coding 3’ UTR region. This model expresses the human VEGFA protein. B6-hVEGFA mice can be used for mechanistic studies and efficacy evaluations of ophthalmic diseases such as Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and corneal neovascularization, as well as for tumor development and cancer drug research.
Reference
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004 Dec;56(4):549-80.
Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019 Mar 7;176(6):1248-1264.
Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, Neves A, Passarinha LA, Tomaz CT. Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives. Cytokine Growth Factor Rev. 2018 Feb;39:102-115.
Chekhonin VP, Shein SA, Korchagina AA, Gurina OI. VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets. 2013 May;13(4):423-43.
Strain Strategy
The sequence from the CTG start codon to 3'UTR of the mouse Vegfa gene was replaced with the sequence from the CTG start codon to 3'UTR of the human VEGFA gene.
Figure 1. Gene editing strategy of B6-hVEGFA mice.
Application Area
Research on Age-Related Macular Degeneration (AMD);
Research on Diabetic Retinopathy (DR);
Research on corneal neovascular diseases;
Tumor development and cancer drug research.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.